New York, New York, United States
Raised $3.5b in capital at $ROIV. Sold Myovant ($MYOV) and Urovant ($UROV) to Sumitomo ($4506.T) in landmark collaboration. Currently lead all activities in technology and computational drug discovery. Built 8 companies in last 3 years that have raised $100m+ during that period. Chair boards of VantAI, Psivant, Zest, Haystack, and others. Previously co-founded a retail financial services startup, grew it to 25k+ customers. In past lifetimes, worked as a chef in rural France and studied nuclear stuff.
Led spinout of VantAI. Closed partnerships with BMS and Blueprint within six months of spinout. Leading platform for design of PROTACs, molecular glues, and other PPI modulators. Most advanced platform to predict PPIs.
Led spinout of Psivant Therapeutics in partnership with Woody Sherman. Using molecular dynamics to design small molecules against hard-to-drug targets
Led ideation and creation of Haystack Health, world's first value-based clinical trial recruitment platform.
Led ideation, inception, and growth of Zest Dermatology, the first and only value-based medical dermatology practice